Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed…
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc.…
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 13, 2025 16:01 ET Â | Source: Nurix Therapeutics, Inc. SAN FRANCISCO,…
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025 16:05 ET Â | Source: TELA Bio, Inc. MALVERN, Pa.,…
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…
Fibe Unveils Digital FDs, Strengthening Its Role as a One-Stop Financial Partner
Enables investments without a linked savings account, with options from top banks…
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence…